UK patients gain early access to Duchenne drug
28 Jun 2017
Some news regarding the drug Raxone.
Raxone (idebenone) has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).
"As a result of the decision, patients aged 10 and above with respiratory function decline, who are not taking gluticorticoids, will be able to get access to Raxone ahead of formal approval by the European Medicines Agency.
The aim of the EAMS is to provide patients with life threatening or seriously debilitating conditions access to unapproved treatments when there is a clear unmet medical need.
Santhera has already filed the drug with the EMA, and it is now under review for the rare inherited muscle wasting disease."
For more information, please see the full article here in Pharmphorum.com.
Full link: https://pharmaphorum.com/news/uk-patients-get-early-access-duchenne-drug/
COPYRIGHT 2014 HARRISON’S FUND
ALL RIGHTS RESERVED | REGISTERED UK CHARITY NO. 1146662
SITE BY MZURI DESIGN